ARTHUR-D.-LITTLE
2.6.2020 10:02:12 CEST | Business Wire | Press release
Arthur D. Little (ADL) today announced the acquisitions of Cutter Consortium, a business technology research company based in the US, and Presans, a leading player in industrial open innovation based in France. By combining its own expertise with an existing community of independent experts, ADL expands its consulting ecosystem to establish a next-generation value proposition powered by open consulting and open problem solving.
Cutter Consortium (www.cutter.com ) helps organizations navigate digital disruption of business models and leverage emerging technologies for competitive advantage and mission success. Through its research, consulting, training, and executive education – all delivered by globally recognized thought leaders – Cutter delivers innovative solutions to its thousands of clients worldwide. Cutter’s experts have done the ground-breaking work in areas ranging from digital architectures to digital tech, enterprise agility to data analytics, and digital leadership to sustainable innovation. At the heart of its business is a membership service that gives clients valuable access to its experts and their insight.
Presans (www.presans.com ) is a leading data-driven platform dedicated to industrial open innovation and open problem solving. Thanks to cutting-edge technology based on big data and artificial intelligence, as well as a team of fellows (former research and innovation executives) with in-depth knowledge in innovation, Presans leverages a network of over 6 million experts worldwide. Presans provides a variety of high-end open innovation services, contributing to the acceleration of decision-making and removal of scientific and technological roadblocks. Presans has worked for 50+ international industrial groups and delivered more than 100 innovation projects in Europe, the US and the Middle East.
“Arthur D. Little applies an ‘open consulting’ and ‘open problem solving’ approach and brings the best global experts to every assignment to complement its internal strengths,” comments Ignacio García Alves, Chairman and CEO of Arthur D. Little . “We believe the future is open consulting. With the double acquisition of Cutter and Presans, we are able to expand our open consulting ecosystem and open problem solving capabilities, offering access to experts, premium insight and a differentiated experience for our clients, in a seamless way.”
“The Cutter team felt an instant synergy with our colleagues at ADL. We share a focus on innovation, which, in ADL’s case, goes back to its roots, and an emphasis on providing custom, leading-edge solutions. Moreover, ADL’s more than 40 offices in 30 countries has given Cutter an enhanced ability to assist its clients worldwide,” says Karen Coburn, CEO of Cutter Consortium .
“Since its inception at the École Polytechnique's start-up incubator, Presans has always engaged with the best experts in the world, mainly to help its customers solve complex technical problems,” says Albert Meige, Founder of Presans . “Presans now addresses more and more problems at the crossroads of strategy consulting and scientific & technical expertise. The time had therefore come for Presans to strengthen itself by joining forces with Arthur D Little.”
Together with Cutter and Presans, ADL reinforces its position on digital and information technologies, as well as industrial innovation, particularly in breakthrough innovation and convergence problem solving. In addition, through the acquisition of the technological platform of Presans, ADL is accelerating its investments in artificial intelligence and machine learning to develop state-of-the-art offerings for its clients.
Cutter Consortium and Presans will continue to operate under their current brands with the same management teams, while benefiting from ADL’s capabilities, investment, and global exposure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005080/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom